Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
62 hedge funds and large institutions have $133M invested in Agile Therapeutics in 2016 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 11 reducing their positions, and 1 closing their positions.
1,100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 1
45% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 11
22% more funds holding
Funds holding: 51 → 62 (+11)
20% less capital invested
Capital invested by funds: $167M → $133M (-$33.8M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$2.45M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$1.4M |
| 3 |
DM
Deerfield Management
New York
|
+$1.04M |
| 4 |
PVI
Pura Vida Investments
New York
|
+$981K |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$827K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$3.55M |
| 2 |
AC
Aisling Capital
New York
|
-$3.31M |
| 3 |
PA
Perceptive Advisors
New York
|
-$2.51M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.91M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$1.04M |
AGRX Hedge Fund Activity: Q4 2016 in Review
62 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2016, worth a combined $133M — down 20% from $167M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AGRX positions and 1 closed out — a net gain of 11 holders — while 16 added to existing stakes and 11 trimmed.
The largest buyer was Caxton Corporation, adding an estimated $2.45M. The largest seller was Vivo Capital, cutting an estimated $3.55M.
- 62 institutional investors held Agile Therapeutics (AGRX) as of Q4 2016, up from 51 in Q3 2016.
- Funds reported $133M of Agile Therapeutics stock for Q4 2016, down 20% quarter-over-quarter.
- 12 funds opened new Agile Therapeutics positions in Q4 2016 and 1 closed out, a net change of +11 holders.
- The largest Agile Therapeutics buyer in Q4 2016 was Caxton Corporation, an estimated $2.45M added.
- The largest Agile Therapeutics seller in Q4 2016 was Vivo Capital, an estimated $3.55M sold.
Based on aggregated 13F filings for Q4 2016.